SCHEMBL1784890

SCHEMBL1784890

CCON(OCC)OCC

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5551514 0.96
Hydrochloric Acid SCHEMBL5548371 0.96
Water SCHEMBL4252402 0.96 ACHE (0.31)
SCHEMBL19551323 0.96
Cyclopropane SCHEMBL7622646 0.89
SCHEMBL8529437 0.81
Acetic Acid SCHEMBL5551646 0.80 FFAR3 (0.41) SOAT1
Phosphine SCHEMBL28117916 0.78
SCHEMBL24599984 0.75
SCHEMBL11237588 0.70 ACHE (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3956304-B1 SPECIFIC DEHYDROGENATION PROCESS (I) DSM IP ASSETS BV (NL) 2026-03-25 EP claimed
CN-113677662-B Specific dehydrogenation process (I) 帝斯曼知识产权资产管理有限公司 2024-07-16 CN claimed
US-11851402-B2 Specific dehydrogenation process (I) DSM IP ASSETS B.V. (NL) 2023-12-26 US claimed
US-20230068017-A1 DEHYDROGENATION PROCESS DSM IP ASSETS B.V. (NL) 2023-03-02 US claimed
EP-4081505-A1 DEHYDROGENATION PROCESS DSM IP Assets B.V. (NL) 2022-11-02 EP claimed
CN-114829338-A Dehydrogenation process 帝斯曼知识产权资产管理有限公司 2022-07-29 CN claimed
US-20220194891-A1 SPECIFIC DEHYDROGENATION PROCESS (I) DSM IP ASSETS B.V. (NL) 2022-06-23 US claimed
EP-3956304-A1 SPECIFIC DEHYDROGENATION PROCESS (I) DSM IP Assets B.V. (NL) 2022-02-23 EP claimed
WO-2021130057-A1 DEHYDROGENATION PROCESS DSM IP ASSETS B.V. (NL) 2021-07-01 WO claimed
WO-2020212163-A1 SPECIFIC DEHYDROGENATION PROCESS (I) DSM IP ASSETS B.V. (NL) 2020-10-22 WO claimed
CN-103834221-B Fluoroalkyl phosphonate/ester composition 罗门哈斯公司 2019-05-03 CN claimed
US-5208028-A GELLED EMULSION PARTICLES AND COMPOSITIONS IN WHICH THEY ARE PRESENT HELENA RUBINSTEIN, INC. (US) 1993-05-04 US claimed
EP-0269949-B1 PROCESS FOR PRODUCING A HIGH PURITY QUATERNARY AMMONIUM HYDROXIDE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1993-04-21 EP claimed
US-4776929-A Process for production of quaternary ammonium hydroxides MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1988-10-11 US claimed
CN-122029216-A Polyhydroxy amide compound, negative photosensitive resin composition, dry film, cured product, and electronic component 太阳控股株式会社 2026-05-12 CN disclosed
EP-3956304-B1 SPECIFIC DEHYDROGENATION PROCESS (I) DSM IP ASSETS BV (NL) 2026-03-25 EP disclosed
WO-2025100236-A1 POLYHYDROXYAMIDE COMPOUND, NEGATIVE PHOTOSENSITIVE RESIN COMPOSITION, DRY FILM, CURED PRODUCT, AND ELECTRONIC COMPONENT 太陽ホールディングス株式会社 2025-05-15 WO disclosed
US-4526857-A Processing photosensitive element provided with layer of photosensitive silver halide emulsion and layer of image receiving element containing 1,2,4-triazole with composition comprising alkali, hydroxylamine, solvent FUJI PHOTO FILM CO., LTD. (JP) 1985-07-02 US disclosed
US-4514488-A Silver salt diffusion transfer process using hydroxylamine and pyrazolidinone developing agents FUJI PHOTO FILM CO., LTD. (JP) 1985-04-30 US disclosed
EP-0137223-A2 Photographic image-receiving element for silver salt diffusion transfer process FUJI PHOTO FILM CO., LTD. (JP) 1985-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194891-A1 SPECIFIC DEHYDROGENATION PROCESS (I) ADH5, ADH4, CYP3A4 SOAT1 1555/4885
US-11851402-B2 Specific dehydrogenation process (I) ADH5, ADH4, CYP3A4 SOAT1 1555/4885
US-20230068017-A1 DEHYDROGENATION PROCESS ALDH1A2, ALDH1A3, ADH4 SOAT1 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.